Three years of ibrutinib in CLL
Three years of ibrutinib in CLL
In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment
2455-2456
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
16 April 2015
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Abstract
In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment
Other
2455.full.pdf_sso-checked=true
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 10 March 2015
Published date: 16 April 2015
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 380238
URI: http://eprints.soton.ac.uk/id/eprint/380238
ISSN: 0006-4971
PURE UUID: 65ae1979-334d-427c-815d-17cd97208940
Catalogue record
Date deposited: 04 Sep 2015 15:00
Last modified: 15 Mar 2024 03:41
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
